Compare Marriott International Inc (MAR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Sanofi SA — how do they compare? Marriott International Inc trades at $365 (market cap $96.76B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Marriott International Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| MAR | SNY | |
|---|---|---|
Market Cap | $96.76B | $104.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $52.34 |
52-Week Low | $255.35 | $41.33 |
Enterprise Value | $113.71B | $121.32B |
Dividend Yield | 0.8% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $367.81, up 0.43% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $26.19B and net income of $2.60B, with a P/E of 38.42 and P/B of 443.63 indicating high valuation. Recent news includes strategic partnerships and the upcoming Q2 2026 earnings report on August 3, 2026.
The outlook is cautious due to high valuation and bearish technicals, but analyst consensus suggests a 5.6% upside to the $388.33 price target. Risks include rising debt-to-asset ratio (58.83% in 2025) and competitive pressures, while opportunities lie in travel demand growth and loyalty program strength.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
